NIAID BAA: Development of Therapeutic Medical Countermeasures For Biodefense and Emerging Infectious Diseases
The National Institute of Alergies and Infectious Diseases (NIAID) has just issued a Braod Agency Announcement (BAA) on Development of Therapeutic Medical Countermeasures For Biodefense and Emerging Infectious Diseases.
Funding: NO CAPON THE BUDGET, up to 5 years
Application Due Date: October 1, 2012
The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.
Therapeutics supported under this BAA:
Broad spectrum anti-bacterial: Therapeutic with activity against one of the following bacterial pathogens:Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, and Rickettsia prowazekii AND in addition, activity against one other NIAID Category A, B and C bacterial threat agent.
Broad spectrum anti-viral: Therapeutic with activity against one of the following viral pathogens: Ebola virus, Marburg virus, Variola major, Dengue virus, Venezuelan encephalitis virus, Western Equine encephalitis virus, and Eastern Equine encephalitis virus AND, in addition, activity against one other NIAID Category A, B and C viral threat agent
Influenza antiviral agents: Therapeutics active against multiple influenza A subtypes directed at either viral or host targets.
Anti-toxins supported under this BAA are specified as the following: A therapeutic agent, particularly a small molecule, with activity against one of the following toxins: Botulinum neurotoxin, Staphylococcus enterotoxin B, Bacillus anthracis Protective Antigen, Lethal Factor or Edema Factor, and ricin toxin.
This BAA will NOT support:
- Basic research and discovery of new candidates/products.
- Refinement of a lead series to identify a lead candidate.
- Development of devices or diagnostics.
- Development of candidates/products that have not demonstrated activity in a relevant animal model of disease.
To schedule a call with a representative from FreeMind please contact Hannah Rosencweig at:
(617) 648-0340, hannah@